Shares of Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) traded down 2.9% during trading on Tuesday . The stock traded as low as $41.30 and last traded at $41.47. 5,525,892 shares were traded during trading, a decline of 58% from the average session volume of 13,077,118 shares. The stock had previously closed at $42.70.
Analyst Ratings Changes
Several research analysts have issued reports on the stock. Wolfe Research cut shares of Tempus AI from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 26th. Bank of America boosted their price objective on shares of Tempus AI from $54.00 to $60.00 and gave the stock a "neutral" rating in a report on Monday, March 3rd. TD Cowen reiterated a "buy" rating and set a $74.00 target price (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Morgan Stanley boosted their price target on Tempus AI from $50.00 to $60.00 and gave the stock an "overweight" rating in a research note on Thursday, March 6th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Tempus AI in a research report on Tuesday, February 25th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $61.18.
Get Our Latest Report on TEM
Tempus AI Stock Performance
The company's 50 day moving average price is $56.19 and its two-hundred day moving average price is $50.92. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.
Insider Activity at Tempus AI
In other Tempus AI news, Director Jennifer A. Doudna sold 1,320 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $90.00, for a total value of $118,800.00. Following the completion of the transaction, the director now directly owns 36,011 shares in the company, valued at $3,240,990. This represents a 3.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the firm's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $60.00, for a total transaction of $826,200.00. Following the sale, the chief accounting officer now owns 57,237 shares in the company, valued at $3,434,220. The trade was a 19.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,581,969 shares of company stock worth $316,538,582.
Institutional Trading of Tempus AI
Several institutional investors and hedge funds have recently added to or reduced their stakes in TEM. Operose Advisors LLC purchased a new stake in Tempus AI during the 4th quarter valued at approximately $25,000. Farther Finance Advisors LLC purchased a new position in Tempus AI during the fourth quarter valued at $34,000. Prestige Wealth Management Group LLC grew its stake in Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after acquiring an additional 965 shares in the last quarter. NewEdge Advisors LLC bought a new stake in Tempus AI in the 4th quarter valued at $49,000. Finally, First Horizon Advisors Inc. lifted its stake in Tempus AI by 207.9% in the 4th quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company's stock worth $55,000 after purchasing an additional 1,108 shares in the last quarter. Institutional investors own 24.22% of the company's stock.
About Tempus AI
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Further Reading
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
